



**FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY**

**EMBARGOED: NOT FOR PUBLICATION BEFORE 09.00AM GMT ON 5 OCT 2018**

## **Mundipharma announces Philippe Bastide as Head of Biosimilars**

- Philippe brings over 25 years' experience in pharma/ biotechnology to the new role
- Experience setting up and managing biosimilar units for Amgen and Shire/Baxalta

**Cambridge, UK, 5 October 2018** – The Mundipharma network of independent associated companies today confirmed the appointment of Philippe Bastide who joins as Head of Biosimilars, Mint Commercial, reporting to Chris Surridge, European Director of Strategy and Commercial Excellence.

He brings with him drive and experience gained from over 25 years' pharma experience. His career includes over five years of Biosimilar experience with both Amgen and Shire, in both European and Global commercial roles. Philippe started the Amgen European Biosimilars organisation then led the overall Shire/ Baxalta Biosimilars Unit.

Commenting on his appointment, Philippe said: "Mundipharma has built a reliable and extremely successful biosimilars platform, making them the biosimilars partner of choice in Europe. I believe my global experience, coupled with the commercial skill and collective desire to explore innovative new ways to ensure healthcare systems continue to benefit from biosimilars, will be a winning combination."

Chris Surridge, European Director of Strategy and Commercial Excellence, added: "Our market leading biosimilars platform is a core component of our growth strategy. Philippe's focus will be on ensuring continued commercial success, while accessing further opportunities to expand both our portfolio and geographically remit, building out our capabilities to do so."



**FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY**

**Notes to editors:**

**About the Mundipharma network**

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: [www.mundipharma.com](http://www.mundipharma.com)

**For further information please contact:**

Alison Dyson

[Alison.dyson@mundipharma.com](mailto:Alison.dyson@mundipharma.com)

T: +44 (0)1223 397 346